Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureRobert M. Wenham, Rebecca Kristeleit, Daniela Matei, Sharad Ghamande, Ana Oaknin, Jonathan S. Berek, J. Alejandro Perez-Fidalgo, Pau Guillén Sentís, Eva M. Guerra Alia, June Hou, Phillipe Follana, Lauriane Eberst, Andrew Clamp, Jean-Sebastien Frenel, Patricia Roxburgh, Robert H. Jones, Patricia Pautier, Amanda L. Jackson, Deborah K. Armstrong, Tingting Song, Maiko Nomoto, Natalyn Hawk, Rachael Scott, Vicky Makker
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
Folate receptor alpha in advanced epithelial ovarian cancer: diagnostic role and therapeutic implications of a clinically validated biomarker
10.3390/ijms26115222 · 2025
Folate receptor alpha—a novel approach to cancer therapy
10.3390/ijms25021046 · 2024
Exploring the therapeutic use and outcome of antibody-drug conjugates in ovarian cancer treatment
10.1038/s41388-025-03448-3 · 2025
Advances in antibody-drug conjugates for endometrial cancer
10.1158/1535-7163.mct-24-0763 · 2025
Unresolved referenced work
2025
Unresolved referenced work
Kept as external metadata until matched
Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer
10.1056/nejmoa2309169 · 2023
First-in-human phase 1 study of MORAb-202, an antibody-drug conjugate comprising farletuzumab linked to eribulin mesylate, in patients with folate receptor-α-positive advanced solid tumors
10.1158/1078-0432.ccr-20-4740 · 2021
Folate receptor alpha for cancer therapy: an antibody and antibody-drug conjugate target coming of age
10.1080/19420862.2025.2470309 · 2025
Results from the first-in-human phase I study of LY4170156, an antibody drug conjugate (ADC) targeting folate receptor alpha in recurrent platinum resistant high-grade serous ovarian cancer (HGSOC) [abstract]
10.1016/j.annonc.2025.08.1707 · 2025
Safety and efficacy of BAT8006, a folate receptor α (FRα) antibody drug conjugate, in patients with platinum-resistant ovarian cancer: update on the dose optimization/expansion cohort of BAT-8006-001-CR trial [abstract]
2025
First-in-human study of AZD5335, a folate receptor α (FRα)-targeted antibody-drug conjugate, in patients with platinum-resistant recurrent ovarian cancer [abstract]
10.1016/j.annonc.2025.08.1705 · 2025
A phase I/II study of rinatabart sesutecan (Rina-S) in patients with advanced ovarian or endometrial cancer [abstract]
2024
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer
10.1016/j.ygyno.2023.01.020 · 2023
Antibody-drug conjugate combinations in cancer treatment: clinical efficacy and clinical study perspectives
2025
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer
10.1016/j.ygyno.2025.06.016 · 2025
Rinatabart sesutecan (Rina-S) for patients with advanced endometrial cancer: first disclosure from dose expansion cohort B2 of the GTC1184–01 study [abstract]
2025
MORAb-202, an antibody-drug conjugate utilizing humanized anti-human FRα farletuzumab and the microtubule-targeting agent eribulin, has potent antitumor activity
10.1158/1535-7163.mct-17-1215 · 2018
Unresolved referenced work
2022
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
Antibody-drug conjugate MORAb-202 exhibits long-lasting antitumor efficacy in TNBC PDx models
10.1111/cas.14898 · 2021
Preclinical and early clinical development of MORAb-202, a folate receptor alpha-targeted antibody-drug conjugate, which utilizes Halaven as payload at first time
2021
10.1016/s0959-8049(22)01032-2
10.1016/s0959-8049(22)01032-2
Antitumor effect of farletuzumab ecteribulin in molecular subtypes of endometrial cancer patient-derived xenograft models
10.1158/1535-7163.mct-25-0035 · 2025
Clinical trial of safety and antitumor activity of farletuzumab ecteribulin in patients with platinum-resistant ovarian cancer: phase I expansion results
2025
Shortening the timeline of pediatric phase I trials: the rolling six design
10.1200/jco.2007.12.7712 · 2008
Pharmacokinetic and exposure-response modeling support body surface area-based dosing of farletuzumab ecteribulin in Japanese patients with solid tumors
10.1002/jcph.6187 · 2025
Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline
10.1200/jco.2017.77.6385 · 2018
Management of interstitial lung disease associated with connective tissue disease
2016
A confidence interval for the median survival time
10.2307/2530286 · 1982
Treatment-related adverse events of antibody-drug conjugates in clinical trials: a systematic review and meta-analysis
10.1002/cncr.34507 · 2023
10.1016/s0090-8258(21)00717-4
10.1016/s0090-8258(21)00717-4 · 2021
Eribulin-induced interstitial pneumonia: a case series and retrospective cohort study
10.2169/internalmedicine.2779-19 · 2020
Unresolved referenced work
2025
No additional external references are available.